secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-281199
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech reports Q3 net loss $15.7M; Phase 3 melanoma trial site activation accelerates; cash $151.2M
--------------------------------------------------------------------------------

- Net loss $15.7M (vs $4.5M in Q3 2021); R&D expenses $10.0M (up from $4.1M) driven by Phase 3 trial costs.
- Cash $151.2M as of Sep 30, 2022 (down from $211.5M at Dec 31, 2021); expected to fund operations into mid-2024.
- Phase 3 trial site activation accelerated: 55 sites actively enrolling (up from 19 at end of July 2022).
- Updated Phase 1/2 data: median OS 46.8 mo, median PFS 22.5 mo, complete response rate 50% in PD-1 naive patients.
- Named Amy Sullivan as CFO in October 2022; new clinical collaboration with Merck for neoadjuvant/adjuvant trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/0001193125-22-281199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522281199/d412247d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer